AVITA Medical reports developments in therapeutic acute wound care, led by the RECELL platform for Spray-On Skin used in burn and trauma wounds. Company news commonly covers FDA-cleared wound-care indications, RECELL GO automation, international regulatory clearances, and the U.S. commercial portfolio that includes Cohealyx, a collagen-based dermal matrix, and PermeaDerm, a biosynthetic wound matrix.
Updates also include clinical data presentations, BARDA emergency-preparedness agreements, quarterly financial results, investor-conference participation, and board or executive governance changes. The recurring news themes connect AVITA Medical's product platform with acute burn care, trauma wound treatment, commercialization, reimbursement, and capital resources.
AVITA Therapeutics (NASDAQ: RCEL) announced its plans to release Q1 2021 financial results on November 11, 2020, after market close. A conference call to discuss these results will follow at 1:30 PM Pacific time. The company focuses on regenerative medicine, particularly with its RECELL® System for treating burns, which received FDA approval in September 2018. This system significantly reduces donor skin requirements and has been used in over 8,000 patients worldwide.